Peripheral IV Vasopressors: How Risky, Really?

Delayed vasopressor initiation kills. CVC placement takes time, and isn't free of its own risk. The question is whether the peripheral route is actually as dangerous as tradition assumes.

Central venous catheters have been the traditional default for vasopressor infusion largely out of concern for extravasation and tissue necrosis — concerns that trace back partly to individual case reports (skin necrosis after IV norepinephrine, BMJ 1955; skin necrosis after vasopressin extravasation, Crit Care Med 2002). But CVC placement carries its own immediate risks (arrhythmia, vascular injury, pneumothorax) and delayed ones (DVT, bloodstream infection), and takes time to place — time during which a hypotensive patient isn't getting pressor support. The 2021 Surviving Sepsis Campaign formally recommended starting vasopressors peripherally rather than delaying for central access, which makes this exactly the right moment for a large, current evidence synthesis.

Pain, swelling, infiltration, extravasation, cellulitis, thrombophlebitis — real, but manageable conservatively.

Note the epinephrine and metaraminol confidence intervals are wide (0–24.6% and 0.1–11.5%) — fewer catheters means less precision, not necessarily a truly higher ceiling of risk.

This is the paper's central, clinically actionable finding.

The practical payoff metric, and the one most directly relevant to your own department's protocol design.

Across 38 studies (15,371 catheters) reporting it, the pooled CVC avoidance proportion was 59.7% (95% CI 46.4–71.7), but individual studies ranged from 0% to 100%. The OR and ward settings showed significantly higher avoidance than ICU/ED/mixed settings — largely because OR peripheral pressor use is typically for transient anesthesia-related hypotension under intensive monitoring, while ED/ICU peripheral use often functions as a bridge to, rather than a replacement for, eventual central access. Midline catheters showed significantly higher CVC avoidance than short PIV (83.8% vs. 58.1%, P<.001) — the flip side of their higher VTE signal: they buy more days off a central line at the cost of measurably more clot risk.

• Retrospective studies significantly underreport minor AEs compared with prospective studies and RCTs (1.5% vs. 4.5% vs. 11.1%, P<.001) — consistent with under-ascertainment of mild, self-limited events in chart-review-driven cohorts. Since 63% of the included studies were retrospective, the pooled 2.3% headline figure is likely a floor, not a ceiling, on true minor AE incidence.
• Post-2021 studies report significantly higher minor AE rates than pre-2021 studies (3.4% vs. 1.4%, P=.048) — the authors attribute this to increased peripheral pressor adoption and reporting vigilance following the 2021 Surviving Sepsis Campaign recommendation, not to the practice becoming less safe over time.

• 61.2% of included studies were rated unclear or high risk of bias, mainly for lack of standardized AE ascertainment methods and missing confidence intervals in the source studies.
• Considerable heterogeneity (I² up to 95.2% for pooled minor AEs) reflects real variation in study design, protocols, and clinical settings — this limits how confidently the pooled point estimates generalize to any single department's practice.
• Dosage and concentration data were inconsistently reported and could not be analyzed — this review cannot tell you whether higher-dose peripheral norepinephrine carries materially more risk than lower-dose.
• The authors are explicit: no high-quality RCT has directly compared PIV against CVC for AE outcomes, so this synthesis should not be read as license to categorically replace CVCs with PIVs — only as evidence that short-term, monitored short-PIV vasopressor use carries a low measured complication rate.

Across the largest dataset assembled on this question to date, short peripheral IV catheters placed in proximal veins carried an essentially negligible major-complication rate (0.0%, one tissue necrosis event in ~29,600 catheters) and a low minor-complication rate (2.3% overall, mostly self-limited). The real caution flag in this whole dataset is specifically the midline catheter subgroup, where VTE risk was meaningfully higher (1.4%) — plausibly a dwell-time effect rather than a drug effect, but real enough to warrant deliberate duration limits and monitoring if midlines are your institution's chosen route. None of this replaces individualized judgment about when central access is still the right call (prolonged infusion, need for other central-line-dependent therapies, difficult peripheral access) — but for short-term, appropriately monitored pressor support via a short PIV catheter in a proximal vein, the evidence base for caution has gotten a lot thinner than the traditional teaching implies.

• ZhangJian S-J, Niu K-Y, Chen C-B, Seak C-J, Yen C-C. Incidence of Adverse Events in Peripheral Intravenous Vasopressor Use: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2026;9(3):e260710. doi:10.1001/jamanetworkopen.2026.0710.
• Owen VS, Rosgen BK, Cherak SJ, et al. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis. Crit Care. 2021;25(1):146.
• Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247.
• Teja B, Bosch NA, Diep C, et al. Complication rates of central venous catheters: a systematic review and meta-analysis. JAMA Intern Med. 2024;184(5):474–482.
• Delaney A, Finnis M, Bellomo R, et al. Initiation of vasopressor infusions via peripheral versus central access in patients with early septic shock: a retrospective cohort study. Emerg Med Australas. 2020;32(2):210–219.